Bausch + Lomb Completes Acquisition of Xiidra Eye Drops and Other Ophthalmology Assets

VAUGHAN, Ontario—Bausch + Lomb Corporation announced it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye, and certain other ophthalmology assets.  Read more...

The National Average for Gross Revenue at ECP Locations Decreased for the Week of Sept. 18–24, Jobson’s Latest Practice Performance Tracker Shows

NEW YORK—The national average for gross revenue at ECP locations decreased last week (September 18 – September 24) when compared with the previous week at a rate of -5 index points.  Read more...

Johnson and Johnson Vision Announces Launch of ‘Vision Made Possible’

JACKSONVILLE, Fla.—Johnson & Johnson Vision, a part of Johnson & Johnson MedTech, announced the launch of Vision Made Possible, a global effort to raise awareness and ignite conversation about the importance of eye health across all ages and stages of vision.  Read more...



September 2023

September 2023


20/20 Pro to Pro Continuing Education